Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DR26FSGX3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,484.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, issued on November 14, 2025, with an ultimate completion date of December 8, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. will perform the work at its Park Ridge, Illinois facility.
This delivery order is issued under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (IDC) with the DLA Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which carries a $500 million ceiling and extends through December 31, 2036. The PPV-G GEN V represents the DLA's $30.3 billion strategic pharmaceutical supply initiative designed to support recurring medical supply needs across military healthcare facilities worldwide. DMS Pharmaceutical Group serves as one of multiple regional prime vendor contractors under this umbrella program, positioning the company as a critical supplier within the Department of Defense healthcare supply chain. The contractor has demonstrated substantial federal performance through numerous prior delivery orders spanning diverse pharmaceutical categories including specialty biologics, oncology treatments, vaccines, and emergency medications.
Quick answers
Who was awarded contract SPE2DR26FSGX3?
SPE2DR26FSGX3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 14, 2025.
How much is contract SPE2DR26FSGX3 worth?
The government has obligated $10,485 on SPE2DR26FSGX3.
Is contract SPE2DR26FSGX3 an order under another contract?
Yes. SPE2DR26FSGX3 is a delivery order under SPE2DR25D9305, an indefinite delivery contract.
Was contract SPE2DR26FSGX3 competed?
The extent of competition for SPE2DR26FSGX3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award